Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries
A Single Site Randomized, Clinical Trial Comparing the Concomitant Use of MicroMatrix® With Cytal™ Wound Matrix 2-Layer to Standard of Care in Patients With Stage 3 or 4 Pressure Injuries
Sponsor: Integra LifeSciences Corporation
Listed as NCT03283787, this NA trial focuses on Pressure Ulcer and Pressure Ulcer, Stage IV and remains completed. Sponsored by Integra LifeSciences Corporation, it has been updated 14 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Oct 2022 — Dec 2022 [monthly]
Completed NA
▶ Show 9 earlier versions
-
May 2021 — Oct 2022 [monthly]
Completed NA
-
Jan 2021 — May 2021 [monthly]
Completed NA
-
Dec 2020 — Jan 2021 [monthly]
Completed NA
-
Jun 2020 — Dec 2020 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting NA
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting
-
Oct 2019 — Jan 2020 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Oct 2017 — Oct 2019 [monthly]
Recruiting NA
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Integra LifeSciences Corporation
- St Vincent's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .